The sales process of Ratiopharm gained pace on Wednesday when it emerged that seven trade buyers and private equity groups were competing for the world’s fourth-largest generic drugs group.

People close to the situation said four financial investors – Cinven, a consortium of Goldman Sachs and Advent International, TPG and Kohlberg Kravis Roberts – had handed in offers for the company.